Newlink Genetics Cor PT Raised to $21.00 (NLNK)
Several other analysts have also recently commented on the stock. Analysts at Robert W. Baird reiterated an “outperform” rating on shares of Newlink Genetics Cor in a research note to investors on Monday, February 11th. They now have a $20.00 price target on the stock. Analysts at MLV Capital initiated coverage on shares of Newlink Genetics Cor in a research note to investors on Thursday, January 3rd. They set a “buy” rating and a $18.50 price target on the stock.
Two analysts have rated the stock with a buy rating, and one has assigned an overweight rating to the company’s stock. Newlink Genetics Cor currently has a consensus rating of “buy” and an average price target of $18.83.
Newlink Genetics Cor traded down 0.59% on Friday, hitting $11.70. Newlink Genetics Cor has a 1-year low of $8.32 and a 1-year high of $18.00. The stock’s 50-day moving average is currently $11.97. The company’s market cap is $244.7 million.
NewLink Genetics Corporation (NewLink) is a development-stage company. The Company is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.